|
**Overview**: Autoimmune Interstitial Lung Disease Panel**Introduction**: The Autoimmune Interstitial Lung Disease Panel is a diagnostic tool designed to screen for interstitial lung diseases with autoimmune etiology using serum samples. In India, connective tissue disease-associated ILD (e.g., scleroderma, myositis) is common, with prevalence 10-30 percent in rheumatology cohorts and high burden in women with Raynaud's or arthritis. Antibodies like anti-Jo-1, anti-Scl-70, anti-Ro-52 indicate progressive fibrosis. High morbidity from underdiagnosis in rural areas, limited HRCT/pulmonology access, overlap with TB/post-TB fibrosis, delayed immunosuppression leading to respiratory failure. Per pulmonology practices aligned with ICMR and Indian Chest Society guidelines, the test employs immunoassay for antibody detection over 1-2 days with high sensitivity/specificity, valuable for identifying autoimmune drivers in ILD. This diagnostic falls under autoimmune screening and targets patients with suspected CTD-ILD, addressing accurate detection to guide therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing fibrosis progression. Its serum-based approach ensures reliable detection.**Other Names**: Auto ILD Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded for CTD-ILD; in India, prominence with rising rheumatology-pulmonology overlap.**Purpose**: The test screens for 8 parameters including anti-Jo-1 to guide ILD assessment, identify autoimmune triggers, inform immunosuppressive therapy.**Test Parameters**: 1. Anti-Jo-1, 2. Anti-PL-7, 3. Anti-PL-12, 4. Anti-Mi-2, 5. Anti-Ku, 6. Anti-Scl-70, 7. Anti-Ro-52, 8. Anti-PM-Scl.**Pretest Condition**: No fasting required; patients should report dyspnea, dry cough, joint pain, Raynaud's.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on dyspnea, cough, joint symptoms, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated ILD including respiratory failure, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate autoimmune ILD, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Pulmonologists or rheumatologists should be consulted for management.**Additional Supporting Tests**: HRCT chest, PFTs for confirmation.**Test Limitations**: May miss rare antibodies; comprehensive approach required.**References**: Indian Journal of Chest Diseases 2024, ILD Studies India 2023. |
